Post-market surveillance (PMS) of artemether-lumefantrine fixed-dose Combinations marketed in Benin
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In Benin, several studies still confirm the circulation of low-quality
anti-malarial drugs, despite efforts to improve the supply chain. It is, therefore,
necessary to carry out post-market quality surveillance of the same to ensure that
only quality and efficacious medicines are sold to the general populace. The aim of
this work was to evaluate the post-market quality of fixed-dose combinations of
artemether-lumefantrine marketed in Benin. This descriptive and analytical study
was executed in four stages over fourteen months, from December 2019 to January
2021. Thirty samples of artemether-lumefantrine (80/480 mg) fixed-dose
combination tablets were collected from sixteen pharmacies in Cotonou and Porto
Novo. The various quality control activities and tests conducted were: visual
identification, pharmacopoeial tests (weight uniformity and disintegration tests),
identification tests, in-vitro comparative dissolution tests and active ingredients
content determination by HPLC-UV. The results of our analyses showed that none
of the samples passed the visual identification test; all the samples passed the weight
uniformity test in accordance with the specifications of the European pharmacopeia
(Eur Ph). Regarding the identification tests of the active substances, we noted a clear
overlap between the spectra of the reference and all the samples. However, one
sample had a low content of the active ingredients (acceptance criteria of 90-110%
for both lumefantrine and artemether). Also, two samples did not pass the
disintegration test). The dissolution profiles of lumefantrine in these 3 samples,
compared to that of Coartem® Princeps, were different (ƒ2A = 19.59 ƒ2B = 9.91
ƒ2C = 41.42; <50).This study confirms the circulation of substandard drugs and the
need for post-market surveillance of other pharmaceuticals sold in Benin in order to
guarantee that only drugs that meet the quality standards are sold to consumers.
